Strength Seen in AngioDynamics (ANGO): Can Its 23.3% Jump Turn into More Strength?

AngioDynamics (ANGO) shares ended the last trading session 23.3% higher at $8.63. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.8% loss over the past four weeks.

The sharp upsurge in AngioDynamics' shares can be attributed to the company's announcement that it has received the FDA 510(K) clearance for its NanoKnife System for prostate tissue ablation. The Company received clearance for the NanoKnife System for prostate tissue ablation following the completion of the pivotal PRESERVE clinical study and submission of results to the FDA in September. The study evaluated the safety and effectiveness of the system for ablating prostate tissue in patients with intermediate-risk prostate cancer.

This medical device maker is expected to post quarterly loss of $0.11 per share in its upcoming report, which represents a year-over-year change of -120%. Revenues are expected to be $71.17 million, down 10% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For AngioDynamics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ANGO going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

AngioDynamics is part of the Zacks Medical - Instruments industry. Thermo Fisher Scientific (TMO), another stock in the same industry, closed the last trading session 1.5% higher at $537.23. TMO has returned -4.1% in the past month.

For Thermo Fisher, the consensus EPS estimate for the upcoming report has changed -0.3% over the past month to $5.92. This represents a change of +4.4% from what the company reported a year ago. Thermo Fisher currently has a Zacks Rank of #3 (Hold).

Zacks Naming Top 10 Stocks for 2025

Want to be tipped off early to our 10 top picks for the entirety of 2025?

History suggests their performance could be sensational.

From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2025. Don’t miss your chance to get in on these stocks when they’re released on January 2.

Be First to New Top 10 Stocks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report

AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report

Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.